We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+3.16%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.43B
AUM Growth
+$53M
Cap. Flow
+$216M
Cap. Flow %
8.89%
Top 10 Hldgs %
47.1%
Holding
78
New
18
Increased
12
Reduced
15
Closed
20

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$82.2M
2
ALKS icon
Alkermes
ALKS
+$81.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$62.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$61.1M
5
GERN icon
Geron
GERN
+$55.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$85.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$68.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$56.9M
4
IMVT icon
Immunovant
IMVT
+$39.5M
5
ALBO
Albireo Pharma Inc
ALBO
+$36.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
76
DELISTED
Albireo Pharma Inc
ALBO
– –
-1,704,000
Closed -$36.8M
HZNP
77
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-500,000
Closed -$56.9M
HZNP
78
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-500,000
Closed -$56.9M
1 2 3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Deep Track Capital held 78 positions worth $2.43B, up 2.2% from $2.38B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deep Track Capital deployed $216M of net new capital in Q1 2023, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $39.5M trimmed.

  • Deep Track Capital's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2023, an estimated $61.1M increase.
  • Deep Track Capital's biggest Q1 2023 reduction was Immunovant, cutting an estimated $39.5M.
  • Deep Track Capital fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $85.5M.
  • Deep Track Capital's ten largest holdings make up 47% of its $2.43B portfolio in Q1 2023.
  • Deep Track Capital opened 18 new positions and closed 20 in Q1 2023.
  • Deep Track Capital's portfolio value rose 2.2% quarter-over-quarter to $2.43B.

Based on Deep Track Capital's 13F filing for Q1 2023, filed 15 May 2023.